Recent Posts

• Eyenovia’s Presentation at the Ladenburg Thalmann Healthcare Conference Wednesday July 14, 2021 July 14, 2021
• Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue June 15, 2021
• Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia May 25, 2021